AZD9833 clinical trials
Also written AZD9833 and Camizestrant.
ClinicalTrials.gov finds 17 studies for AZD9833. How that becomes 20 here
Every study that search finds has been read, to see whether and how it gives AZD9833. ClinicalTrials.gov counts as of Nov 17, 2026. How drug pages count
- 17Found by its intervention search · See all 17 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 12 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +5Give it under a name that search misses: a biosimilar’s code or a misspelling
- 22Give AZD9833 to participants
- −2Give it beside what is tested
- 20Test it: the count on this site
Get an email when these change. Save the AZD9833 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 4 Sept 2026 · ETCAMAH · NDA 220359 (FDA, Drugs@FDA)
- European Union
- 20 Jul 2026 · Etcamah · EMEA/H/C/006494 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 2 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 3
AstraZeneca (17) · University Health Network, Toronto (1) · UNICANCER (1) · MedSIR (1)
Often tested with
Tested in the same studies.
Celecoxib (1) · AZD5305 (1) · Letrozole (1) · Atirmociclib (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 2 most studied
New when their studies opened, with AZD9833 beside them; studies of each.
- 1Gatsuciclib
- 1AZD5305
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test AZD9833, phase 3 first.
Studies
Open first, then newest update. How each study uses AZD9833 has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 20
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT06380751With saruparib, or with a CDK4/6 inhibitorWritten as CamizestrantReport a problem
- A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT07647328With ribociclib, a phase 3b studyWritten as CamizestrantReport a problem
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyRecruitingPhase 3AstraZenecaNCT05774951Adjuvant switch after two years of endocrine therapy (CAMBRIA-1)Written as CamizestrantReport a problem
- Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerRecruitingPhase 2AstraZenecaNCT07427394With new atirmociclibWritten as CamizestrantReport a problem
- Phase II Study of CAmizestrant in Resectable Endometrial AdenocarcinomaNot yet recruitingPhase 2University Health Network, TorontoNCT07840443Before surgery in endometrial cancerWritten as CamizestrantReport a problem
- Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.Not yet recruitingPhase 3UNICANCERNCT07717450Switched to with abemaciclib on rising ctDNAReport a problem
- Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerRecruitingPhase 2MedSIRNCT07195227With ribociclib, before its approvalWritten as CamizestrantReport a problem
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseActive, not recruitingPhase 3AstraZenecaNCT04711252Against anastrozole with palbociclib (SERENA-4)Written as AZD9833Report a problem
- Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active, not recruitingPhase 3AstraZenecaNCT04964934On the US labelSwitched to on ESR1 mutation before progression (SERENA-6)Written as AZD9833Report a problem
- A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast CancerActive, not recruitingPhase 2AstraZenecaNCT04214288Against fulvestrant (SERENA-2)Written as AZD9833Report a problem
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingPhase 1AstraZenecaNCT03616587First-in-human, alone or with CDK4/6 or everolimus (SERENA-1)Written as AZD9833Report a problem
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Active, not recruitingPhase 3AstraZenecaNCT05952557Adjuvant against standard endocrine therapy (CAMBRIA-2)Written as CamizestrantReport a problem
- A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female ParticipantsCompletedPhase 1AstraZenecaNCT06547164Interactions with midazolam and carbamazepineWritten as CamizestrantReport a problem
- A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast CancerCompletedPhase 1AstraZenecaNCT04541433Dose finding in Japanese womenWritten as AZD9833Report a problem
- Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female SubjectsCompletedPhase 1AstraZenecaNCT05790304Single dose across liver impairmentWritten as CamizestrantReport a problem
- A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast CancerCompletedPhase 2AstraZenecaNCT04588298Before surgery, biological effects (SERENA-3)Written as AZD9833Report a problem
- AZD9833 China PK StudyCompletedPhase 1AstraZenecaNCT04818632Pharmacokinetics in Chinese womenWritten as AZD9833Report a problem
- Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female VolunteersCompletedPhase 1AstraZenecaNCT05438303Its effect on probe drugsWritten as AZD9833Report a problem
- A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With ItraconazoleCompletedPhase 1AstraZenecaNCT05551897With itraconazoleWritten as CamizestrantReport a problem
- A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833CompletedPhase 1AstraZenecaNCT04546347Bioavailability and food effectWritten as AZD9833 film-coated tablet A Dose 1Report a problem
Behind its US label · 1 — the studies the FDA label of ETCAMAH describes
From the Clinical Studies section of ETCAMAH (2026-09), as openFDA has it. A study the site does not hold is left out.
Tested on its own · 7 — no other medicine in its arm
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyRecruitingPhase 3AstraZenecaNCT05774951Adjuvant switch after two years of endocrine therapy (CAMBRIA-1)Written as CamizestrantReport a problem
- Phase II Study of CAmizestrant in Resectable Endometrial AdenocarcinomaNot yet recruitingPhase 2University Health Network, TorontoNCT07840443Before surgery in endometrial cancerWritten as CamizestrantReport a problem
- A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast CancerActive, not recruitingPhase 2AstraZenecaNCT04214288Against fulvestrant (SERENA-2)Written as AZD9833Report a problem
- A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast CancerCompletedPhase 1AstraZenecaNCT04541433Dose finding in Japanese womenWritten as AZD9833Report a problem
- Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female SubjectsCompletedPhase 1AstraZenecaNCT05790304Single dose across liver impairmentWritten as CamizestrantReport a problem
- A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast CancerCompletedPhase 2AstraZenecaNCT04588298Before surgery, biological effects (SERENA-3)Written as AZD9833Report a problem
- A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833CompletedPhase 1AstraZenecaNCT04546347Bioavailability and food effectWritten as AZD9833 film-coated tablet A Dose 1Report a problem
Tested with established drugs · 10 — they are given beside it
- A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT07647328With ribociclib, a phase 3b studyWritten as CamizestrantReport a problem
- Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.Not yet recruitingPhase 3UNICANCERNCT07717450Switched to with abemaciclib on rising ctDNAReport a problem
- Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerRecruitingPhase 2MedSIRNCT07195227With ribociclib, before its approvalWritten as CamizestrantReport a problem
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseActive, not recruitingPhase 3AstraZenecaNCT04711252Against anastrozole with palbociclib (SERENA-4)Written as AZD9833Report a problem
- Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active, not recruitingPhase 3AstraZenecaNCT04964934On the US labelSwitched to on ESR1 mutation before progression (SERENA-6)Written as AZD9833Report a problem
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingPhase 1AstraZenecaNCT03616587First-in-human, alone or with CDK4/6 or everolimus (SERENA-1)Written as AZD9833Report a problem
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Active, not recruitingPhase 3AstraZenecaNCT05952557Adjuvant against standard endocrine therapy (CAMBRIA-2)Written as CamizestrantReport a problem
- A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female ParticipantsCompletedPhase 1AstraZenecaNCT06547164Interactions with midazolam and carbamazepineWritten as CamizestrantReport a problem
- AZD9833 China PK StudyCompletedPhase 1AstraZenecaNCT04818632Pharmacokinetics in Chinese womenWritten as AZD9833Report a problem
- A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With ItraconazoleCompletedPhase 1AstraZenecaNCT05551897With itraconazoleWritten as CamizestrantReport a problem
Tested in a combination · 3 — another drug in the study is under test too
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT06380751With saruparib, or with a CDK4/6 inhibitorWritten as CamizestrantReport a problem
- Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerRecruitingPhase 2AstraZenecaNCT07427394With new atirmociclibWritten as CamizestrantReport a problem
- Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female VolunteersCompletedPhase 1AstraZenecaNCT05438303Its effect on probe drugsWritten as AZD9833Report a problem
Beside a new treatment under test · 2 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with AZD9833: Gatsuciclib 1 · AZD5305 1
- A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1/2AstraZenecaNCT06188520Partner of new gatsuciclib with CDK4/6 inhibitorsWritten as CamizestrantReport a problem
- Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingPhase 1/2AstraZenecaNCT04644068Partner of new saruparib in one moduleWritten as CamizestrantReport a problem
Codes
What other systems call AZD9833 · ClinicalTrials.gg INT001822
- MeSH (NLM) C000722187AZD9833One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722187 | AZD9833 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.